Revolution Medicines, Inc. (RVMD)

Revolution Medicines Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	11.58	35.38	29.39	42.98
Revenue Growth (YoY)	-	-67.27%	20.38%	-31.62%	-14.10%
Cost of Revenue	592.23	411.24	253.07	186.95	132.25
Gross Profit	-592.23	-399.66	-217.69	-157.56	-89.27
Selling, General & Admin	97.3	62.02	40.59	30.45	21.43
Operating Expenses	97.3	62.02	40.59	30.45	21.43
Operating Income	-689.52	-461.69	-258.28	-188.01	-110.7
Interest Expense	-	-0.3	-	-0.01	-0.07
Interest & Investment Income	86.88	47.48	9.15	0.93	2.24
Other Non Operating Income (Expenses)	1.8	0.12	-	-	-
EBT Excluding Unusual Items	-600.85	-414.39	-249.13	-187.09	-108.53
Merger & Restructuring Charges	-	-25.5	-	-	-
Pretax Income	-600.85	-439.89	-249.13	-187.09	-108.53
Income Tax Expense	-0.75	-3.52	-0.42	-	-0.37
Net Income	-600.09	-436.37	-248.71	-187.09	-108.16
Preferred Dividends & Other Adjustments	-	-	-	-	2.22
Net Income to Common	-600.09	-436.37	-248.71	-187.09	-110.38
Shares Outstanding (Basic)	168	113	81	73	55
Shares Outstanding (Diluted)	168	113	81	73	55
Shares Change (YoY)	48.24%	40.34%	10.74%	32.68%	1879.16%
EPS (Basic)	-3.58	-3.86	-3.08	-2.57	-2.01
EPS (Diluted)	-3.58	-3.86	-3.08	-2.57	-2.01
Free Cash Flow	-567.74	-358.3	-235.22	-153.71	-103
Free Cash Flow Per Share	-3.38	-3.17	-2.92	-2.11	-1.88
Gross Margin	-	-	-	-	-207.68%
Operating Margin	-	-3986.92%	-730.01%	-639.70%	-257.54%
Profit Margin	-	-3768.28%	-702.95%	-636.58%	-256.80%
Free Cash Flow Margin	-	-3094.14%	-664.83%	-522.99%	-239.62%
EBITDA	-683	-456.68	-254.34	-184.96	-108.12
EBITDA Margin	-	-	-	-	-251.54%
D&A For EBITDA	6.53	5.01	3.94	3.05	2.58
EBIT	-689.52	-461.69	-258.28	-188.01	-110.7
EBIT Margin	-	-	-	-	-257.54%
Revenue as Reported	-	11.58	35.38	29.39	42.98

Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q